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Abstract. Imaging biomarkers in neuro-oncology are used for diagnosis, prog-
nosis and treatment response monitoring. Magnetic resonance imaging is typi-
cally used throughout the patient pathway because routine structural imaging 
provides detailed anatomical and pathological information and advanced tech-
niques provide additional physiological detail.  
 
Following image feature extraction, machine learning allows accurate classifi-
cation in a variety of scenarios. Machine learning also enables image feature ex-
traction de novo although the low prevalence of brain tumours makes such ap-
proaches challenging.  
 
Much research is applied to determining molecular profiles, histological tumour 
grade and prognosis at the time that patients first present with a brain tumour. 
Following treatment, differentiating a treatment response from a post-treatment 
related effect is clinically important and also an area of study. Most of the evi-
dence is low level having been obtained retrospectively and in single centres. 
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1 Introduction 
1.1 Imaging Biomarkers 
A biomarker can be defined as a characteristic that is measured as an indicator of 
normal biological processes, pathogenic processes, or responses to an exposure or 
intervention, including therapeutic interventions [1]. Molecular, histologic, imaging, 
or physiologic characteristics are types of biomarkers. In neuro-oncology, imaging 
biomarkers are used for diagnosis, prognosis and treatment response monitoring.  
Magnetic resonance imaging is typically used throughout the patient pathway 
because routine structural imaging provides detailed anatomical and pathological 
information and advanced techniques provide additional physiological detail. 
Qualitative analysis of a new intracranial mass aides diagnosis and in routine clinical 
practice can determine whether or not to proceed to confirmatory biopsy or resection. 
For example, with some basic demographic information such as the age of the patient 
and with some basic clinical information, such as knowledge that the mass was found 
incidentally whilst imaging for an unrelated condition, the qualitative routine 
structural imaging features of a grade 1 meningioma allow diagnosis with a high 
positive predictive value without the need for confirmatory biopsy. Advanced 
techniques allow quantitative analysis of masses which can also change management. 
For example, cerebral blood volume values obtained using dynamic susceptibility-
weighted imaging within an area of tumour contrast enhancement, or 1H-magetic 
resonance spectroscopic ratios acquired from a tumour, may help determine whether a 
mass is of high histological grade (grade III or IV) in certain scenarios.  
Some image analysis recommendations, which determine treatment response of 
high histological grade gliomas, have become common in the research setting and rely 
on simple linear metrics of simple image features, namely the product of the maximal 
perpendicular cross-sectional dimensions of contrast enhancing tumour [2,3]. 
 
Unlike the above biomarkers where simple imaging features are apparent to the re-
porting clinician, much image analysis research aims to extract underlying infor-
mation from the imaging dataset to develop biomarkers that may not be readily visi-
ble. Machine learning can be applied to different phases of image analysis research 
which sequentially consists of pre-processing images, feature estimation (quantifying 
or characterizing the image), feature selection (remove noise and random error in the 
underlying data), classification (decision or discriminant analysis) and evaluation [4].  
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1.2 Clinical Validity 
Evaluation in image analysis research initially consists of analytical validation, where 
accuracy and reliability of the biomarker are assessed [5]. Accuracy determines how 
often a test is correct in a given population (the number of true positives and true neg-
atives divided by the number of overall tests). Clinical validation is the testing of bi-
omarker performance in a clinical trial. Biomarkers in neuro-oncology may not be rig-
orously proven to be analytically or clinically valid [5]. Validation instead may attempt 
to use a common biomarker thereby reducing the clinical validity. For example, an at-
tempt to validate a new imaging biomarker for treatment response monitoring may in-
volve comparing it to a common biomarker for treatment response, such as the product 
of the maximal perpendicular cross-sectional dimensions of contrast enhancing tumour. 
However, the common biomarker itself may not be rigorously proven to be clinically 
valid.  
 
This update describes several illustrative research studies with a variety of de-
signs aimed at developing imaging biomarkers for diagnosis, prognosis and treatment 
response monitoring using machine learning. Different machine learning strategies 
used in classification in particular, as well as feature estimation and selection, are 
demonstrated. The extent of analytical and clinical validation is highlighted. As with 
the illustrative studies described here, most research studies pertaining to machine 
learning and neuro-oncology are pioneering but the level of evidence is low [6]. Af-
terall, most studies are retrospective and performed in single centres. 
2 Diagnostic Biomarkers 
2.1 Pre-diagnostic Biomarkers 
Pre-diagnostic or risk or susceptibility biomarkers are typically clinical or molecular 
and occur in the absence of overt neuro-oncological disease. An example could be the 
discovery of a patient with Li-Fraumeni syndrome. This is a hereditary cancer syn-
drome due to mutations in the tumour suppressor gene p53 where patients have a sus-
ceptibility for the development of glioma. Other examples include DNA repair gene 
polymorphisms, single-nucleotide polymorphisms and a history of ionizing radiation 
[5]. Imaging has had a negligible contribution to neuro-oncological pre-diagnosis. 
 
 
2.2 Diagnostic Biomarkers 
Diagnostic biomarkers are used to detect or confirm the presence of a disease or a 
subtype of the disease [1]. Both histology and molecular features are now frequently 
combined and 1p/19q chromosome arm co-deletion status and isocitrate dehydrogen-
ase (IDH) mutation status are routinely acquired after biopsy in accordance with the 
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2016 World Health Organization Classification of Tumors of the Central Nervous 
System [7]. There has been much research using machine learning to extract molecu-
lar information from imaging, known as radiomics. The results have been promising 
but prospective clinical validation is required [5].  
 
Example 1. The aim of this retrospective study was to use a machine-learning algo-
rithm to generate a model predictive of IDH mutant status in high-grade gliomas 
based on clinical variables and multimodal features extracted from pre-operative rou-
tine MRI [8]. True IDH mutant status was determined following biopsy using a com-
bination of immunohistochemistry, spectrometry and sequencing. The authors suggest 
that knowing the pre-operative IDH mutant status might counter the limited sensitiv-
ity of immunohistochemistry and might influence the extent of tumour resection, alt-
hough there is limited evidence for these assertions. Pre- and post-contrast T1-
weighted, T2-weighted, and apparent diffusion coefficient map images were obtained. 
Whole tumour, enhancing and non-enhancing tumour volumes as well as a tumour 
border region were segmented. Subregions delimited by apparent diffusion coefficient 
thresholds within the three volumes were also segmented. Imaging descriptors includ-
ing location, first and second order (textural) statistics gave 2970 extracted features. 
Feature selection was performed using area under the receiving-operator characteristic 
curve (AUC) threshold and correlation. The remaining 386 features were used to 
build a model predictive of IDH mutant status by applying random forest to a 90 pa-
tient training dataset. The tree depth was set to 64 with a 4096 tree upper bound limit 
and bootstrapping applied. Ten-fold cross validation was used. This gave 86% accu-
racy with an AUC of 0.88. The model was tested on a 30 patient in test dataset giving 
89% accuracy and 0.92 AUC.  
Heterogeneity metrics associated with ADC-delineated segmentation were 
the imaging features that contributed most in predicting IDH mutant status. Despite 
the multiple complex imaging features such as these, patient age gave the highest pre-
dictive value of IDH mutant status demonstrating the importance of including simple, 
accessible information as features in radiomic analyses. Unfortunately, other simple 
data such as Karnofsky Performance Status, which is known to be an important co-
variate in multivariate analyses of glioma survival, was not included. Nonetheless, the 
overall approach shows that machine learning allows combinations of features to be 
combined to give higher accuracy than single features alone including age.  
A strength of the study is that routine imaging alone was used which makes 
translation to the clinic more feasible than if advanced imaging algorithms were also 
included. This is due to a frequent lack of standardization in many advanced imaging 
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algorithms.  
Common to most studies of diagnostic biomarkers, a limitation is that the 
findings relate to a single institution therefore the findings cannot be generalized else-
where. Secondary high grade glioma were excluded, which presumably relates to ex-
clusion of low grade gliomas that were followed up and then transformed. It is also 
noted that only enhancing tumours were included. Within the institution, the model 
can only be used within these constraints. 
Example 2. In a similar retrospective study, a machine-learning algorithm was also 
applied to multimodal features extracted from pre-operative routine MRI to generate a 
model predictive of IDH mutant status (84 patients) [9]. In this example, grade II and 
III gliomas were studied and 1p/19q chromosome arm co-deletion status (67 patients) 
was also predicted as was grade (84 patients). Pre- and post-contrast T1-weighted, 
T2-weighted/FLAIR images were obtained from The Cancer Genome Atlas (TCGA)/ 
The Cancer Imaging Archive (TCIA) dataset. Imaging descriptors with similarities to 
the previous study such as location, derived from Visually Accessible Rembrandt Im-
ages (VASARI), as well as second order statistics were determined.  
Second order (textural) statistics and VASARI features were independently 
applied to raw images that had undergone a variety of manipulations such as down-
sampling or grey-scale thresholding, using different sequences to give 3360 extracted 
features. Feature selection was performed using logistic regression and bootstrapping 
was performed to maximize the area under the receiving-operator characteristic curve 
giving models with < 10 features. Using this methodology alone, second order statis-
tic models performed better than VASARI models predicting IDH1 mutation status, 
1p/19q co-deletion status and histological grade with AUCs of 0.86, 0.96, and 0.86, 
respectively. Random forest using 500 trees was then applied to combinations of 
clinical features and the two models of selected imaging features. IDH mutation sta-
tus, 1p/19q co-deletion and histological grade were predicted with AUCs of 0.86, 0.89 
and 0.78. Overall, texture played a dominant role in prediction. It is noteworthy that 
prediction of 1p/19q co-deletion status and grade was more accurate with logistic re-
gression and bootstrapping methodology alone than when used as an input for random 
forest.  
Analytical validation with a separate test dataset is required to improve ana-
lytical validity and make the findings more meaningful. However, even with further 
analytical validation the findings are unlikely to be translatable to the clinic as the 
fundamental constraint for clinical validation is that there was a priori knowledge that 
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there were no grade IV gliomas in the dataset.  
Example 3. In this small retrospective study a voxel-based unsupervised clustering 
method used a batch-learning self-organizing map (SOM) followed by k-means to de-
termine regional histological grade from pre-operative routine MRI [10]. SOM is a 
neural network which can simplify features and remove outliers. k-means can identify 
features with similar patterns. Pre- and post-contrast T1-weighted and T2-
weighted/FLAIR images from 36 patients with grade II-IV gliomas were processed 
and 161,157 extracted features underwent this two-level clustering to give clustered 
image maps. Segmented clustered image map regions corresponding to enhancing tu-
mour tissue, non-enhancing tumour tissue, and oedematous tissue were described as 
class ratios which were used as inputs for supervised analysis. Classification was by a 
linear kernel support vector machine (SVM) using leave-one-out cross validation to 
distinguish low and high grade gliomas. The clustered image map with the optimal 
number of cluster classes gave an accuracy of 0.86 with 0.93 AUC. It was noted that a 
phenotype for high grade gliomas included high intensity of post-contrast T1-
weighted and FLAIR images in contrast enhancing regions whereas a low grade phe-
notype showed high intensity of T2 images in these regions. Information from con-
trast enhancing regions alone made a large contribution to grade prediction with an 
accuracy of 0.82.  
The method was applied prospectively to 4 patients with analysis of targeted 
biopsy tissue from representative classes which gave some limited evidence that the 
clusters gave meaningful information. It is noteworthy that no clinical parameters 
were used. Although this is a single centre study with a small number of patients, and 
without robust clinical validation, the approach to diagnostic biomarker development 
is an exemplar for how to minimise a priori knowledge. 
3 Monitoring Biomarkers 
Monitoring biomarkers are measured serially and may detect change in extent of dis-
ease, provide evidence of treatment exposure or assess safety [1]. There is an overlap 
with safety biomarkers which specifically determine any treatment toxicity. Monitor-
ing blood or cerebral spinal fluid for circulating tumor cells, exosomes, and mi-
croRNAs shows promise [5]. However, imaging is particularly useful as it is non-in-
vasive and captures the entire tumour volume and adjacent tissues and has led to rec-
ommendations to determine treatment response in trials [2,3]. Clinical validation is 
typically not proven. Common biomarkers are frequently used in an attempt to indi-
rectly validate the monitoring biomarker under development. 
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Example 1. The aim of this small glioblastoma study was to use a machine-learning 
algorithm to differentiate progression from pseudoprogression, at the earliest time 
point when an enlarging MRI-enhancing lesion is seen, using T2-weighted images 
alone [11]. Unsupervised feature estimation was performed using principal compo-
nent analysis to investigate topological descriptors of image heterogeneity called Min-
kowski functionals. After confounders were identified (MRI field strength) and sensi-
tivity to field strength demonstrated, a supervised analysis was performed. Feature se-
lection reduced Minkowski functional, first order statistical and clinical features from 
32 to 7. A radial basis function kernel support vector machine gave an accuracy of 
0.88 in a retrospective training dataset of 17 patients and 0.86 in a prospective test da-
taset of 7 patients. Although not apparent to the reporting radiologist, the T2-weighted 
hyperintensity phenotype of those patients with progression was heterogeneous, large 
and frond-like when compared to those with pseudoprogression. The pseudoprogres-
sion phenotype on T2-weighted images was shown to be a distinct entity and different 
from vasogenic oedema and radiation necrosis. 
 
Additional analytical validation was performed firstly in the form of reliabil-
ity testing which showed that a different operator performing segmentation achieved 
100% classification concordance. Secondly, the same results using a different soft-
ware package and a different operator were also obtained. Thirdly, a different feature 
selection method (random forest) and classifier (lasso) were used and also gave the 
same accuracy with 6 similar selected features.  
A strength of the study is that T2-weighted images alone were used increas-
ing the chance of translation. However, the study was performed in a single centre 
and, as the authors point out, the biomarker requires clinical validation in a larger 
multicentre test dataset.  
Example 2. The aim of this small high grade glioma study was to use a machine-
learning algorithm to differentiate progression from pseudoprogression at the earliest 
time point when an enlarging MRI-enhancing lesion is seen, using [18F]-fluoroethyl-
L-tyrosine positron emission tomography [12]. First and second order statistics were 
obtained from the images of 14 patients and underwent unsupervised consensus clus-
tering. The cumulative distribution function then determined the optimal class size. 
Feature selection by predictive analysis of microarrays methodology using 10-fold 
cross validation reduced the features from 19 to 10. One of the 3 class PET-based 
clusters could differentiate progression and pseudoprogression, however the results 
were similar to the standard analysis method using maximal tracer uptake in the tumor 
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divided by that in normally appearing brain tissue. The small, single centre study will 
require more analytical and clinical validation as the authors acknowledge. 
4 Prognostic Biomarkers 
Prognostic biomarkers identify the likelihood of a clinical event, recurrence, or pro-
gression based on the natural history of the disease [1]. They are generally associated 
with specific outcome such as overall survival or progression-free survival. Some mo-
lecular markers are prognostic biomarkers therefore there is some overlap with diag-
nostic biomarkers used to predict molecular markers (including IDH mutation status 
and 1p/19q co-deletion status). 
 
Example 1. The aim of this retrospective study was to use a machine-learning algo-
rithm to determine overall survival using imaging features from pre-operative routine 
MRI in patients with glioblastoma [13]. Pre- and post-contrast T1-weighted, FLAIR, 
DSC and diffusion tensor imaging (DTI) images were obtained from a retrospective 
training dataset of 105 patients. Enhancing tumour tissue, non-enhancing tumour tis-
sue, and oedematous tissue regions were segmented with the glioma image segmenta-
tion and registration (GLISTR) segmentation algorithm which produced imaging de-
scriptors including location and first order statistics and limited demographic infor-
mation. From > 150 features, 60 features with the best survival prediction following 
10-fold cross validation were feature selected. Two linear kernel SVMs were used to 
classify patients as survivors or not at 6 and 18 months respectively and a combined 
prediction index calculated. Tenfold cross validation was used to determine the gener-
alization accuracy of the predictive models to give an accuracy of 77% for the predic-
tion of short/medium/long survivors. A prospective test dataset of 29 patients to gave 
an accuracy of 79%.  
Simple data such as Karnofsky Performance Status, which is known to be an 
important co-variate in multivariate analyses of glioma survival, were not included. 
An insightful aspect of this study is that histograms were produced in order to under-
stand the predictive features: greater age, large tumour size, increased tumour diffu-
sivity, larger regions of T2 hypointensity and highest perfusion peak heights, were all 
predictive of short survival. Although the findings have a plausible biological basis, 
translation is limited as this was performed in a single centre. 
 
Example 2. The aim of this retrospective study was to use a machine-learning algo-
rithm to determine overall survival of patients with high grade glioma using brain tu-
mor segmentation (BRaTS) data [14]. Pre- and post-contrast T1-weighted, T2-
weighted and FLAIR images were obtained from a retrospective training dataset of 
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163 patients. Segmented regions including enhancing tumour tissue, non-enhancing 
tumour tissue, and oedematous tissue regions were manually segmented. Features 
were selected by simple features such as location; discrete wavelet transform first and 
second order statistics; histograms alone; and a convolutional neural network (CNN) 
which gave over 4000 deep features. The CNN, AlexNet, used in transfer learning 
context consisted of five convolutional layers followed by three fully connected lay-
ers, with maximum pooling layers used in between the convolution and fully con-
nected layers.  
Patients were then classified as survivors or not at 10 and 15 months respectively. 
SVM, k-nearest neighbors (KNN), linear discriminant, tree, ensemble, and logistic re-
gression were all independently applied to each set of features. A combination of 
CNN deep features and a linear discriminant classifier with 5-fold cross validation 
gave the best predictive result with a train dataset of 91% accuracy and a test dataset 
of 55% accuracy. Although interesting approaches to developing a prognostic bi-
omarker were employed including using a CNN to generate features, the low test ac-
curacy is suggestive of overfitting. 
5 Conclusion 
Machine learning and neuro-oncology are at an early stage of development and 
are not ready to be incorporated into the clinic as the level of evidence is low. Integra-
tion of data in addition to imaging, including demographic, clinical and molecular 
markers, may lead to increasingly accurate biomarkers. Development and validation 
of machine learning models applied to neuro-oncology require large, well-annotated 
datasets, and therefore multidisciplinary and multicentre collaborations are necessary. 
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